TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2789926

Group type: EXPERIMENTAL
Intervention: BRL 24924 2 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: BRL 24924 1 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 20
Study: 4685619

Group type: EXPERIMENTAL
Intervention: Phenylephrine with monoamine oxidase inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Noradrenaline with monoamine oxidase inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adrenaline with monoamine oxidase inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isoprenaline with monoamine oxidase inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phenylephrine with imipramine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Noradrenaline with imipramine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adrenaline with imipramine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isoprenaline with imipramine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Noradrenaline and adrenaline in local anaesthetics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isoprenaline inhalation by bronchial asthmatics
Number of subjects: 0
Study: 29037887

Group type: EXPERIMENTAL
Intervention: Presence of diabetic foot
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Cardio-vascular diseases
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Eye complication
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Erectile dysfunction
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Overall prevalence of depression
Number of subjects: 385

Group type: COMPARATOR
Intervention: Age
Number of subjects: 385

Group type: COMPARATOR
Intervention: Gender
Number of subjects: 385

Group type: COMPARATOR
Intervention: Duration of diabetes
Number of subjects: 385

Group type: COMPARATOR
Intervention: HbA1c levels
Number of subjects: 385
Study: 26111971

Group type: COMPARATOR
Intervention: Braun continuous peripheral nerve block catheter set (n=30)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Novel needle‐over‐cannula (n=30)
Number of subjects: 60
Study: 23906654

Group type: COMPARATOR
Intervention: Complete decongestive physiotherapy (CDP) for 4 days
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Complete decongestive physiotherapy (CDP) for 11 days
Number of subjects: 129
Study: 20299408

Group type: EXPERIMENTAL
Intervention: Fentanyl iontophoretic transdermal system (fentanyl ITS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morphine intravenous (IV) patient-controlled analgesia (PCA)
Number of subjects: 0
Study: 18427444

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open procedures
Number of subjects: 0
Study: 16095600

Group type: EXPERIMENTAL
Intervention: Full-complement red wine (RW)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Dealcoholised red wine (DRW)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Water
Number of subjects: 45
Study: 12696399

Group type: COMPARATOR
Intervention: WHO/ORS (311 mOsml/L)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Low-osmolarity solution (245 mOsm/L)
Number of subjects: 140
Study: 10215673

Group type: EXPERIMENTAL
Intervention: levo-alpha-acetylmethadol (LAAM) 60 mg/70 kg p.o.
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: methadone 60 mg/70 kg p.o.
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: naloxone 1.0 mg/70 kg i.m. after LAAM
Number of subjects: 5

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 5
Study: 8965941

Group type: EXPERIMENTAL
Intervention: Dietary recommendations regarding fibers
Number of subjects: 73

Group type: COMPARATOR
Intervention: Dietary fibers intake
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Dietary and laxative treatment, combined with biofeedback training
Number of subjects: 73
Study: 1829515

Group type: EXPERIMENTAL
Intervention: Recombinant hepatitis B vaccine (20 micrograms) in Group A, 4 doses at 0, 1, 2, and 12 months.
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Recombinant hepatitis B vaccine (10 micrograms) in Group B, 4 doses at 0, 1, 2, and 12 months.
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Recombinant hepatitis B vaccine (20 micrograms) in Group C, 3 doses at 0, 1, and 6 months.
Number of subjects: 110

Group type: COMPARATOR
Intervention: All groups received a dose (145 IU) of hepatitis B immunoglobulin soon after birth.
Number of subjects: 110
Study: 6624186

Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg orally)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Verapamil (160 mg orally)
Number of subjects: 24
Study: 31815085

Group type: EXPERIMENTAL
Intervention: Subcuticular non-absorbable skin sutures (SS)
Number of subjects: 369

Group type: COMPARATOR
Intervention: Skin staples (SC)
Number of subjects: 369
Study: 29299592

Group type: EXPERIMENTAL
Intervention: Fluorouracil, 5% cream (n=468)
Number of subjects: 932

Group type: COMPARATOR
Intervention: Vehicle control cream (n=464)
Number of subjects: 932
Study: 27100440

Group type: EXPERIMENTAL
Intervention: Online Hemodiafiltration (OL-HDF)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional Hemodialysis (HD)
Number of subjects: 20
Study: 24417745

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 165
Study: 22234404

Group type: EXPERIMENTAL
Intervention: Personal Health Record (PHR)
Number of subjects: 453

Group type: COMPARATOR
Intervention: Control group (no PHR)
Number of subjects: 453
Study: 18680634

Group type: EXPERIMENTAL
Intervention: Acid-stable fat emulsion
Number of subjects: 11

Group type: COMPARATOR
Intervention: Acid-unstable fat emulsion
Number of subjects: 11
Study: 17113353

Group type: EXPERIMENTAL
Intervention: 30 mg dextromethorphan and 30 mg morphine combination (MS/DM)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 30 mg morphine (MS)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 15638877

Group type: EXPERIMENTAL
Intervention: Parathyroidectomy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Orthopaedic controls
Number of subjects: 20
Study: 11828809

Group type: EXPERIMENTAL
Intervention: Effective treatments for psychiatric sequelae of trauma
Number of subjects: 0
Study: 10192638

Group type: EXPERIMENTAL
Intervention: Methanesulfonyl fluoride (MSF) at doses of up to 0.18 mg/kg given three times per week for 16 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 7754477

Group type: EXPERIMENTAL
Intervention: Piretanide SR 6 mg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 2271089

Group type: EXPERIMENTAL
Intervention: Fish oil (6 g daily for 1 month)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (6 g coconut oil)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Fish oil (EPA+ re-group)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (EPA- re-group)
Number of subjects: 31
Study: 7282650

Group type: EXPERIMENTAL
Intervention: Visitation condition focusing on conversational interaction
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Visitation condition with cognitively challenging games and conversation
Number of subjects: 49

Group type: COMPARATOR
Intervention: No-treatment control condition
Number of subjects: 49
Study: 29364040

Group type: EXPERIMENTAL
Intervention: Upper Trapezius Dry Needling (UT DN)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Infraspinatus Dry Needling (ISP DN)
Number of subjects: 40
Study: 29122618

Group type: EXPERIMENTAL
Intervention: Tai Chi exercise (one-hour session, five sessions/week during chemoradiotherapy)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Tai Chi exercise
Number of subjects: 114
Study: 26606263

Group type: EXPERIMENTAL
Intervention: i.v. paracetamol (1 g paracetamol + 3.91 g mannitol in 100 ml)
Number of subjects: 24

Group type: COMPARATOR
Intervention: i.v. normal saline (100 ml)
Number of subjects: 24

Group type: COMPARATOR
Intervention: i.v. mannitol (3.91 g mannitol in 100 ml)
Number of subjects: 24
Study: 24647740

Group type: EXPERIMENTAL
Intervention: Electrical carotid sinus stimulator ON
Number of subjects: 16

Group type: COMPARATOR
Intervention: Electrical carotid sinus stimulator OFF
Number of subjects: 16
Study: 21874574

Group type: EXPERIMENTAL
Intervention: Closed suction drains
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Drains designed for re‐transfusion of shed blood
Number of subjects: 120

Group type: COMPARATOR
Intervention: No drain
Number of subjects: 120
Study: 20585236

Group type: EXPERIMENTAL
Intervention: Polyglytone 6211 suture material
Number of subjects: 0

Group type: COMPARATOR
Intervention: Poliglecaprone 25 suture material
Number of subjects: 0
Study: 17427535

Group type: EXPERIMENTAL
Intervention: DEC + ABZ
Number of subjects: 280

Group type: COMPARATOR
Intervention: DEC
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 280
Study: 15105059

Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG) 0.75 mg twice, 12 hours apart
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Mifepristone (MIF) 10 mg, single dose
Number of subjects: 7
Study: 12238831

Group type: EXPERIMENTAL
Intervention: EndothelinA blocker (BQ‐123, 260 nmoL/min for up to 30 minutes)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: EndothelinA blocker (BQ‐123) and endothelinB blocker (BQ‐788, 260 and 250 nmol/min, respectively, for up to 30 minutes)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no endothelin blockers)
Number of subjects: 30
Study: 9439491

Group type: EXPERIMENTAL
Intervention: Interferon alpha‐2b and ribavirin (1000 or 1200 mg per day)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Interferon alpha‐2b and ribavirin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Interferon alpha‐2b and placebo
Number of subjects: 100
Study: 7808647

Group type: EXPERIMENTAL
Intervention: Thymopentin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Thiopental
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40
Study: 2483444

Group type: EXPERIMENTAL
Intervention: Ibopamine 100 mg t.i.d.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Digoxin 0.25 mg o.d.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Washout period
Number of subjects: 10
Study: 1067530

Group type: EXPERIMENTAL
Intervention: Bupivacaine HCL
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 0
Study: 31690170

Group type: EXPERIMENTAL
Intervention: CAREGIVERSPRO-MMD platform
Number of subjects: 74
Study: 30831303

Group type: EXPERIMENTAL
Intervention: Lateral decubitus only
Number of subjects: 106

Group type: COMPARATOR
Intervention: Dorsal and lateral decubitus
Number of subjects: 106
Study: 27813052

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg 3 times a day, n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (n=20)
Number of subjects: 40
Study: 25306290

Group type: EXPERIMENTAL
Intervention: Intermittent walking for 30 minutes every 30 minutes for 120 minutes
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (no walking)
Number of subjects: 13
Study: 24008977

Group type: EXPERIMENTAL
Intervention: Methotrexate (0.05 mg/kg bolus followed by 0.05 mg/kg/h for 6 h)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 80
Study: 21771256

Group type: EXPERIMENTAL
Intervention: Intravenous LPS (2 ng kg(‐1) of actual body weight)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 19800820

Group type: EXPERIMENTAL
Intervention: Spinal analgesia
Number of subjects: 1106

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 1106
Study: 16982264

Group type: EXPERIMENTAL
Intervention: Slow inferior alveolar nerve block (IANB) (60 seconds)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Rapid inferior alveolar nerve block (IANB) (15 seconds)
Number of subjects: 38
Study: 15148541

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 23

Group type: COMPARATOR
Intervention: Untreated (baseline)
Number of subjects: 23
Study: 17344494

Group type: EXPERIMENTAL
Intervention: Soy-nut diet
Number of subjects: 42

Group type: COMPARATOR
Intervention: Soy-protein diet
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control diet (DASH)
Number of subjects: 42
Study: 10364087

Group type: EXPERIMENTAL
Intervention: Lovastatin therapy (60 mg daily)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol supplementation (450 IU daily)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Dummy tablets (control)
Number of subjects: 28
Study: 8645434

Group type: EXPERIMENTAL
Intervention: Strength training (performed twice weekly for 6 months at 70% of one repetition maximum)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no strength training)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 31
Study: 1992319

Group type: EXPERIMENTAL
Intervention: Fluconazole (100 mg daily in the first phase, 200 mg daily in the second phase)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 61
Study: 6416018

Group type: EXPERIMENTAL
Intervention: Erythromycin stearate
Number of subjects: 78

Group type: COMPARATOR
Intervention: Phenoxymethyl penicillin
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 78
Study: 31521192

Group type: EXPERIMENTAL
Intervention: Methotrexate monotherapy after initial treatment with TNF-alpha inhibitor and methotrexate
Number of subjects: 50

Group type: COMPARATOR
Intervention: Matched placebo and methotrexate
Number of subjects: 50
Study: 29266760

Group type: EXPERIMENTAL
Intervention: Adherence to CONSORT guidelines
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Reporting of random allocation and blinding
Number of subjects: 119
Study: 29071949

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) stimulation of Zusanli (ST 36) and Neiguan (PC 6) for 30 min, once daily for 5 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional treatment (control)
Number of subjects: 60
Study: 25175124

Group type: EXPERIMENTAL
Intervention: Intravenous ultra-high dose methylcobalamin (MeCbl), 25 mg/day for 10 days followed by monthly 25 mg for 5 months
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Intravenous ultra-high dose methylcobalamin (MeCbl)
Number of subjects: 14
Study: 21967833

Group type: EXPERIMENTAL
Intervention: Edaravone (30 mg) during t-PA infusion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-Edaravone (no edaravone during t-PA infusion)
Number of subjects: 40
Study: 19563329

Group type: EXPERIMENTAL
Intervention: ABB+PRP
Number of subjects: 87

Group type: COMPARATOR
Intervention: ABB
Number of subjects: 87
Study: 17610451

Group type: EXPERIMENTAL
Intervention: Interferential current application for 20 minutes
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation for 20 minutes
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (not specified in the study)
Number of subjects: 34
Study: 14988829

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg)
Number of subjects: 30
Study: 12052282

Group type: EXPERIMENTAL
Intervention: Lipid disorder therapy (specific treatment for lipid disorder)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lipid disorder therapy (for primary prevention of heart disease)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lipid treatment trials focused on stroke risk reduction
Number of subjects: 0
Study: 9671997

Group type: EXPERIMENTAL
Intervention: Diode laser therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (H2O2 rinse)
Number of subjects: 50
Study: 7924322

Group type: EXPERIMENTAL
Intervention: Progestogen-only contraceptives (pill, DMPA, NET-EN, NORPLANT implants)
Number of subjects: 2466

Group type: COMPARATOR
Intervention: Non-hormonal methods (IUD, barrier methods, sterilization)
Number of subjects: 2466
Study: 2810536

Group type: EXPERIMENTAL
Intervention: Cefamandole (1 gm intravenously every 6 hours for nine doses)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Cefazolin (1 gm intravenously every 6 hours for nine doses)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 47
Study: 30266633

Group type: EXPERIMENTAL
Intervention: Prospective monthly falls diaries
Number of subjects: 9803

Group type: COMPARATOR
Intervention: Retrospective postal questionnaires
Number of subjects: 9803
Study: 28645473

Group type: EXPERIMENTAL
Intervention: Rivaroxaban with non-DHP CCBs
Number of subjects: 1308

Group type: COMPARATOR
Intervention: Warfarin with non-DHP CCBs
Number of subjects: 1308

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 1308

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 1308
Study: 24595903

Group type: EXPERIMENTAL
Intervention: Axitinib
Number of subjects: 714

Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 714
Study: 22995326

Group type: EXPERIMENTAL
Intervention: Fosfomycin trometamol (FMT) 3g, 2 doses separated by 72 hours
Number of subjects: 118

Group type: COMPARATOR
Intervention: Ciprofloxacin 250mg every 12 hours for 3 days
Number of subjects: 118
Study: 21447587

Group type: EXPERIMENTAL
Intervention: Epidural block for at least three postoperative days
Number of subjects: 503

Group type: COMPARATOR
Intervention: General anaesthesia without epidural block
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Epidural block
Number of subjects: 503

Group type: COMPARATOR
Intervention: Control group (no epidural block)
Number of subjects: 503
Study: 19793846

Group type: EXPERIMENTAL
Intervention: 500 mg/d anthocyanins as cyanidin glycosides (from elderberry) for 12 weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 17005061

Group type: EXPERIMENTAL
Intervention: Positive Expiratory Pressure (PEP)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Oscillating Positive Expiratory Pressure (oscillating PEP)
Number of subjects: 15
Study: 15213709

Group type: EXPERIMENTAL
Intervention: Probiotic capsules (containing Lactobacillus acidophilus and Bifidobacterium longum)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 34
Study: 10997466

Group type: EXPERIMENTAL
Intervention: Suture-mediated closure device
Number of subjects: 100

Group type: COMPARATOR
Intervention: Manual compression
Number of subjects: 100
Study: 9338927

Group type: EXPERIMENTAL
Intervention: B. Amor's criteria
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: ESSG criteria
Number of subjects: 841

Group type: EXPERIMENTAL
Intervention: Frequency of spondylarthropathy
Number of subjects: 841

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 841
Study: 8422624

Group type: EXPERIMENTAL
Intervention: FAM-S (5-fluorouracil, doxorubicin, mitomycin C, and streptozotocin)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Phase II single agents (MGBG, DHAD, AZQ)
Number of subjects: 153
Study: 3521208

Group type: EXPERIMENTAL
Intervention: 25 mg hydrochlorothiazide
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 50 mg hydrochlorothiazide
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 50 mg hydrochlorothiazide plus 37.5 mg triamterene
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 50 mg hydrochlorothiazide plus 75 mg triamterene
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (run-in period)
Number of subjects: 26
Study: 30552248

Group type: EXPERIMENTAL
Intervention: Polyphenol-rich brown seaweed extract (2000 mg dose containing 600 mg polyphenols)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo (2000 mg rice flour)
Number of subjects: 58
Study: 27416102

Group type: EXPERIMENTAL
Intervention: Risperidone ISM 50 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Risperidone ISM 75 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Risperidone ISM 100 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Risperidone ISM (all doses)
Number of subjects: 36
Study: 26692164

Group type: EXPERIMENTAL
Intervention: Gluten-Free Diet (GFD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GFD
Number of subjects: 0
Study: 24351996

Group type: EXPERIMENTAL
Intervention: Enneagram group counseling program (38 hours, 8 sessions)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 63
Study: 20202147

Group type: EXPERIMENTAL
Intervention: Budesonide 800 mcg/day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Budesonide 400 mcg/day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Montelukast 5 or 10 mg tablet according to age
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS)
Number of subjects: 60
Study: 18284403

Group type: EXPERIMENTAL
Intervention: Methylprednisolone aceponate (MPA) 0.1% cream twice weekly plus emollient (Advabase)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Emollient alone
Number of subjects: 221
Study: 15665203

Group type: EXPERIMENTAL
Intervention: Therapeutic needle treatment
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo needle treatment
Number of subjects: 59
Study: 12856118

Group type: EXPERIMENTAL
Intervention: Isovolaemic HVHF (6 l/h of replacement fluid) with varying pre-dilution rates
Number of subjects: 8
Study: 10096930

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment consisting of omeprazole, clarithromycin, and tinidazole in H pylori-positive patients and clarithromycin alone in C pneumoniae-positive patients.
Number of subjects: 84

Group type: COMPARATOR
Intervention: No treatment (control group).
Number of subjects: 84
Study: 8902551

Group type: COMPARATOR
Intervention: Placebo (withdrawal group W, n = 12)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ramipril at previous doses (treated group T, n = 8)
Number of subjects: 20
Study: 1866017

Group type: EXPERIMENTAL
Intervention: L-dopa
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6